UY31035A1 - Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson - Google Patents

Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson

Info

Publication number
UY31035A1
UY31035A1 UY31035A UY31035A UY31035A1 UY 31035 A1 UY31035 A1 UY 31035A1 UY 31035 A UY31035 A UY 31035A UY 31035 A UY31035 A UY 31035A UY 31035 A1 UY31035 A1 UY 31035A1
Authority
UY
Uruguay
Prior art keywords
piridin
oxido
carboxamide
parkinson
disease
Prior art date
Application number
UY31035A
Other languages
English (en)
Spanish (es)
Inventor
Delay-Goyet Philippe
Menet Christine
Poughon Gilles
Delgorge Claire
Ravinet Trillou Christine
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY31035A1 publication Critical patent/UY31035A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
UY31035A 2007-04-19 2008-04-18 Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson UY31035A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0702853A FR2915100B1 (fr) 2007-04-19 2007-04-19 Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo- pyridin-4-yl)-5-(methoxy)pyridine-2-carboxalide pour le traitement des desordres moteurs lies a la maladie de parkinson

Publications (1)

Publication Number Publication Date
UY31035A1 true UY31035A1 (es) 2008-11-28

Family

ID=38712405

Family Applications (1)

Application Number Title Priority Date Filing Date
UY31035A UY31035A1 (es) 2007-04-19 2008-04-18 Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson

Country Status (33)

Country Link
US (1) US20100130554A1 (enExample)
EP (1) EP2146714B1 (enExample)
JP (1) JP5386478B2 (enExample)
KR (2) KR101503942B1 (enExample)
CN (1) CN101663035B (enExample)
AR (1) AR066108A1 (enExample)
AT (1) ATE513548T1 (enExample)
AU (1) AU2008257322B2 (enExample)
BR (1) BRPI0810444A2 (enExample)
CA (1) CA2684174C (enExample)
CL (1) CL2008001136A1 (enExample)
CY (1) CY1111840T1 (enExample)
DK (1) DK2146714T3 (enExample)
EA (1) EA019194B1 (enExample)
ES (1) ES2367408T3 (enExample)
FR (1) FR2915100B1 (enExample)
HR (1) HRP20110666T1 (enExample)
IL (1) IL201448A (enExample)
JO (1) JO2678B1 (enExample)
MA (1) MA31367B1 (enExample)
ME (1) ME00935B (enExample)
MX (1) MX2009011284A (enExample)
MY (1) MY148092A (enExample)
NZ (1) NZ580482A (enExample)
PA (1) PA8776801A1 (enExample)
PL (1) PL2146714T3 (enExample)
PT (1) PT2146714E (enExample)
RS (1) RS51869B (enExample)
SI (1) SI2146714T1 (enExample)
TW (1) TWI439269B (enExample)
UY (1) UY31035A1 (enExample)
WO (1) WO2008145841A1 (enExample)
ZA (1) ZA200907251B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2935219A1 (en) * 2012-11-28 2015-10-28 Sanofi METHOD OF PREPARATION OF CRYSTAL FORMS OF 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDOPYRIDYN-4-yl)-5-METHOXYPYRIDINE-2-CARBOXAMIDE AND CRISTAL FORMS THEREOF
US9624100B2 (en) 2014-06-12 2017-04-18 Apple Inc. Micro pick up array pivot mount with integrated strain sensing elements
WO2025079694A1 (ja) * 2023-10-12 2025-04-17 株式会社 メドレックス 経皮吸収組成物
WO2025080415A1 (en) * 2023-10-12 2025-04-17 Alto Neuroscience, Inc. Treatment of neuropsychiatric disorders with tilivapram

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4193926A (en) * 1974-03-20 1980-03-18 Schering Aktiengesellschaft 4-(Polyalkoxy phenyl)-2-pyrrolidones
WO1995004045A1 (en) * 1993-07-28 1995-02-09 Rhone-Poulenc Rorer Limited Compounds as pde iv and tnf inhibitors
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
PT1244649E (pt) * 1999-12-23 2005-06-30 Icos Corp Inibidores de fosfodiesterase especificos de mfa ciclica
WO2002069905A2 (en) * 2001-03-02 2002-09-12 Bristol-Myers Squibb Company Co-administration of melanocortin receptor agonist and phosphodiesterase inhibitor for treatment of cyclic-amp associated disorders
WO2004005258A1 (en) * 2002-07-02 2004-01-15 Merck Frosst Canada & Co. Di-aryl-substituted-ethane pyridone pde4 inhibitors
DE602004032522D1 (de) * 2003-03-12 2011-06-16 Celgene Corp Mit n-alkylhydroxamsäuren substituierte isoindolylverbindungen und deren pharmazeutische verwendung
WO2006135828A2 (en) * 2005-06-10 2006-12-21 Memory Pharmaceuticals Corporation Trisubstituted amines as phosphodiesterase 4 inhibitors
US20070021451A1 (en) * 2005-07-20 2007-01-25 Hamamatsu University School Of Medicine Method for preventing or treating neurologic damage after spinal cord injury

Also Published As

Publication number Publication date
KR20150004885A (ko) 2015-01-13
MY148092A (en) 2013-02-28
EA200970970A1 (ru) 2010-02-26
AU2008257322A1 (en) 2008-12-04
NZ580482A (en) 2011-10-28
MX2009011284A (es) 2009-11-02
EP2146714B1 (fr) 2011-06-22
SI2146714T1 (sl) 2011-10-28
JP2010524906A (ja) 2010-07-22
KR101503942B1 (ko) 2015-03-18
AU2008257322B2 (en) 2013-06-13
ES2367408T3 (es) 2011-11-03
PL2146714T3 (pl) 2011-10-31
EA019194B1 (ru) 2014-01-30
TW200911247A (en) 2009-03-16
US20100130554A1 (en) 2010-05-27
IL201448A (en) 2014-08-31
AR066108A1 (es) 2009-07-22
EP2146714A1 (fr) 2010-01-27
IL201448A0 (en) 2010-05-31
KR20090130059A (ko) 2009-12-17
PA8776801A1 (es) 2008-11-19
PT2146714E (pt) 2011-09-02
HRP20110666T1 (hr) 2011-10-31
CL2008001136A1 (es) 2009-01-16
DK2146714T3 (da) 2011-10-10
CY1111840T1 (el) 2015-10-07
ATE513548T1 (de) 2011-07-15
JO2678B1 (en) 2013-03-03
CA2684174C (fr) 2014-02-25
HK1141725A1 (en) 2010-11-19
ME00935B (me) 2012-06-20
WO2008145841A1 (fr) 2008-12-04
MA31367B1 (fr) 2010-05-03
BRPI0810444A2 (pt) 2016-05-31
FR2915100B1 (fr) 2009-06-05
ZA200907251B (en) 2011-04-28
CA2684174A1 (fr) 2008-12-04
RS51869B (sr) 2012-02-29
FR2915100A1 (fr) 2008-10-24
JP5386478B2 (ja) 2014-01-15
TWI439269B (zh) 2014-06-01
CN101663035A (zh) 2010-03-03
CN101663035B (zh) 2012-06-20

Similar Documents

Publication Publication Date Title
UY30333A1 (es) Uso de flibanserina para el tratamiento de trastornos posmenopausicos del deseo sexual
UY29899A1 (es) Uso de flibanserina para el tratamiento de trastornos del deseo sexual premenopausicos
CL2009000990A1 (es) Uso de epotilona d para el tratamiento de enfermedades asociadas a tau, tal como enfermedad alzheimer, parkinson, entre otras.
PA8772101A1 (es) Imidazol-triazolopirimidinas sustituidas
EA200801758A1 (ru) Лекарственные формы, устойчивые к самовольному изменению
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
PA8784101A1 (es) Oxazolidinonas sustituidas y su uso
AR061446A1 (es) Utilizacion de la 1,7 -dimetilxantina para la fabricacion de un medicamento psicoanaleptico no ansiogeno destinado al tratamiento de un trastorno neuropsiquiatrico
CL2009000402A1 (es) Compuestos derivados de 2-amino-acetamida sustituida; composicion farmaceutica; utiles en el tratamiento de enfermedades pulmonares, enfermedad reumatica, enfermedad autoinmune, entre otras.
DOP2005000025A (es) Compuestos de heteroaril- y fenilsulfamoilo sustituidos
WO2007048801A3 (en) Sexual desire enhancing medicaments comprising benzimidazolone derivatives
HN2009003424A (es) (oxazolidinon-5-il-metil) -2-tiofen-carboxamidas sustituida y su uso en el campo de la coagulacion sanguinea
PT2056804E (pt) Utilização de derivados de 2,5-di-hidroxibenzeno para o tratamento de doenças oculares
BRPI0807804A2 (pt) " arilciclopentenos substituídos como agentes terapêuticos ".
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
UY31035A1 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5)-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de trastornos motores asociados a la enfermedad de parkinson
PY08013253A (es) Utilización de 4-ciclopropilmetoxi-N-(3,5-dicloro-1-oxido-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la médula espinal.
UY31034A1 (es) Utilizacion de 4-ciclopropilmetoxi-n-(3,5-dicloro-1-oxido-4-piridin-4-il)-5-(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos craneales
PE20080455A1 (es) Mirtazapina para el tratamiento de dolor neuropatico
UY29303A1 (es) Medicamentos para el tratamiento o la prevencion de enfermedades fibroticas

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20170926